Search company, investor...

FIT Biotech

fitbiotech.com

Founded Year

1995

Stage

Other Investors | Alive

About FIT Biotech

FIT Biotech is a biotechnology company that develops gene-based treatments. One of the company's products is a DNA vaccine FIT-06 that it is developing for treating HIV.

Headquarters Location

Biokatu 12

Tampere, 33520,

Finland

+358 3 31387000

Missing: FIT Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: FIT Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest FIT Biotech News

ValiRx : Acquisition of Intellectual Property& JV Agreement

May 2, 2019

0 Message : ACQUISITION OF INTELLECTUAL PROPERTY & JOINT VENTURE AGREEMENT ValiRx acquires IP assets of FIT Biotech OY & signs LOI agreement with investor, Alpha Blue Ocean to establish a genetic therapeutic and diagnostic-based Joint Venture London, UK.,02 May 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces:- - the acquisition of the global granted patents and Intellectual Property assets ('IP assets') of FIT Biotech OY ('FIT Bio') for a nominal sum; and - a Letter of Intent ('LOI') agreement with Alpha Blue Ocean ('ABO') to establish a genetic therapeutic and diagnostic-based joint venture ('JV') founded on the acquired technology. ABO is a management company closely affiliated with European High Growth Opportunities SF ('EHGO'). EHGO is an entity with which the Company entered into a subscription agreement which was announced on 26 April 2019. IP assets of FIT Biotech OY ValiRx has entered into a purchase agreement to acquire from the appointed administrator of the bankruptcy estate of FIT Bio, the IP assets of FIT Bio for a consideration of €5,000. FIT Bio, a biotech company, headquartered in Tampere, Finland which was established in 1995 and was publicly listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy. FIT Bio was a company involved in the development of gene delivery technology for a number of indications positioning its technology as an alternative to biologics, such as vaccines, antibodies and protein-based drugs. FIT Bio's principle technology - its Gene Transport Unit platform - had seen an initial product enter into clinical trials. ABO had previously provided finance to FIT Bio - having entered into a financing agreement with FIT Bio in December 2017. Following the termination of this financing agreement FIT Bio was placed into bankruptcy proceedings. ValiRx has acquired the IP assets from the appointed administrator of FIT Bio. Joint Venture Agreement In conjunction with the acquisition of FIT Bio's Intellectual Property assets, ValiRx has signed a Letter of Intent ('LOI') with ABO, an EHGO entity with which the Company entered into a subscription agreement which was announced on 26 April 2019. The agreement is to establish a genetic therapeutic and diagnostic-based joint venture ('JV'), for the further development of FIT Bio's IP assets with the objective to assemble and progress a portfolio of genetic-based technologies. It is envisaged that ValiRx will provide the scientific, technological and clinical development expertise to the JV, whilst ABO will focus on financing the entity and progressing commercial activities. It is also envisaged that ValiRx will add its GeneICE technology, along with the Company's gene silencing compound, VAL101, into the JV portfolio to sit alongside the IP assets of FIT Bio, as the Company believes the portfolio technologies are complementary to each other. ValiRx's GeneICE technology has received two Eurostar awards to date for its technological development. The combined portfolio is well positioned to address the large medical and scientific needs for future precision genetic editing, with all the anticipated technologies in the JV being applicable to many indications, in oncology, inflammation, infectious diseases and neurological conditions. The formation of the JV is subject to further due diligence following the conclusion of scientific and financial analysis. ValiRx and ABO have agreed that discussions and future negotiation are to be conducted on an exclusive basis. Further announcements will be made by the Company in due course. Dr Satu Vainikka, CEO of ValiRx, commented:'The area of genetic editing is a very topical subject area at the moment in the media as gene editing looks set to transform the way we battle a range of diseases. The IP assets of FIT Biotech complement well ValiRx's existing gene-based technologies and their combination will assist the Group in leveraging its position within this medical market place'. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. *** ENDS ***

FIT Biotech Frequently Asked Questions (FAQ)

  • When was FIT Biotech founded?

    FIT Biotech was founded in 1995.

  • Where is FIT Biotech's headquarters?

    FIT Biotech's headquarters is located at Biokatu 12, Tampere.

  • What is FIT Biotech's latest funding round?

    FIT Biotech's latest funding round is Other Investors.

  • Who are the investors of FIT Biotech?

    Investors of FIT Biotech include BioFundnvestment Portfolio II, Aboa Venture Management, Concordia Capital Oy, Sentica Partners, Bio Fund Management and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.